CD276 and ovarian cancer: We have confirmed the preclinical therapeutic potential of B7-H3-targeted and CSPG4-targeted CAR T cells, by showing that they can induce effective and durable antitumor response in murine models of different types of solid tumors, including pancreatic and ovarian cancer, chordoma, glioblastoma and uveal melanoma [16, 24–26].